Management to Share New Findings and Progress from its Clinical Development Programs with Investors and Potential Partners During One-on-One and Small-Group Meetings NEW YORK--(BUSINESS WIRE)--Laxxon Medical Corp. (“Laxxon Medical” or the “Company”), a pharmaceutical technology company developing advanced drug delivery solutions through its proprietary SPID® (Screen Printed Innovative Drugs) technology, today announced that members of its senior management team will hold one-on-one investor...

NEW YORK--( BUSINESS WIRE )--Laxxon Medical, a leading pharmaceutical technology company, pioneering a new generation of advanced oral drug delivery systems, today announced that it will be attending BIO-Europe 2025 and the Jefferies Healthcare Conference, two of the world’s premier partnering events for the Life Sciences industry. “These two conferences are excellent opportunities to engage with forward-thinking leaders and companies seeking innovative solutions to advance drug development,”...

Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.